United States: DNA Primers: The Trouble With Being Short

Last Updated: February 23 2015
Article by Irena Royzman

In BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics Corp. (Ambry), the Federal Circuit invalidated Myriad's claims to short synthetic DNAs. Myriad sued Ambry shortly after the Supreme Court held in Association for Molecular Pathology v. Myriad (Myriad) that Myriad's claims to cDNAs were patent eligible as long as the cDNAs did not have the same sequence as natural DNAs, but that Myriad's claims to isolated genomic DNA (DNA with the same sequence as natural DNA) were not patentable. While commentators have argued that Ambry unnecessarily expands the Supreme Court's holding in Myriad, Ambry flows directly from Myriad's test for patentable subject matter. After Myriad, short synthetic DNAs are not patentable if they have the same sequence as natural DNA.

Ambry involves the medically important BRCA1 and BRCA2 genes that Myriad discovered and isolated. Mutations in these genes are linked to hereditary breast and ovarian cancers. Myriad developed tests for detecting mutations in the BRCA genes, allowing doctors to determine a woman's susceptibility to breast and ovarian cancer. After the Supreme Court invalidated Myriad's claims to isolated BRCA DNAs, competitors including Ambry entered the market with their own tests for BRCA mutations. Just as Myriad, Ambry employs DNA primers patented by Myriad to test for BRCA mutations. These primers – short synthetic DNAs – make it possible to synthesize a patient's BRCA genes using polymerase chain reaction (PCR) and to identify mutations.

Myriad sued Ambry asserting claims in Myriad's patents that were not before the Supreme Court in Myriad. These included claims to a pair of single-stranded DNA primers for PCR so that all or a portion of a woman's BRCA genes could be synthesized and the sequence determined. Although the primers are synthetic and do not occur in nature, the Federal Circuit held that Myriad's claims were invalid. In doing so, the Federal Circuit explained that the primers "necessarily contain the identical sequence of the BRCA sequence directly opposite to the strand to which they are designed to bind."

Following the Supreme Court's decision in Myriad, the Federal Circuit was dismissive of Myriad's argument that primers were patent eligible "because single-stranded DNA cannot be found in the human body." The Federal Circuit emphasized that "[a]s the Supreme Court made clear, neither naturally occurring compositions of matter, nor synthetically created compositions that are structurally identical to the naturally occurring compositions, are patent eligible." It held that "it makes no difference that the identified gene sequences are synthetically replicated."

Myriad also argued that primers have a fundamentally different function than natural DNA sequences and should be patentable for that reason. Here too the Federal Circuit disagreed. It gave no import to the fact that primers make possible the highly unnatural and beneficial amplification of regions of a patient's DNA through PCR. Instead, the Federal Circuit focused on the fact that "just as in nature, primers utilize the innate ability of DNA to bind to itself."

The decision in Ambry follows rather than expands Myriad. Although Myriad upheld the patentability of synthetic BRCA cDNA – DNA synthesized from RNA which only has sequences that code for proteins (exons) and no intervening noncoding sequences (introns) – it did not do so on the basis of cDNA being synthetically created. Rather, the Supreme Court relied on the fact that cDNA is an "exons-only molecule" and therefore has a different sequence than natural DNA, i.e., DNA with both exons and introns.

The Supreme Court also noted that "cDNA is not a 'product of nature' and is patent eligible under §101, except insofar as very short series of DNA may have no intervening introns to remove when creating cDNA." According to the Court, "[i]n that situation, a short strand of cDNA may be indistinguishable from natural DNA." This is the situation in Ambry and why the Federal Circuit's decision, although important, is not surprising in view of Myriad.

After the Supreme Court's decision in Myriad, only short DNAs that span at least two exons with the intervening intron removed are patentable subject matter. This is because such short DNAs do not have the sequence of natural DNAs; they are missing at least one intron. Most short DNAs do not meet these criteria. Moreover, short DNAs do not compensate for being short (and not spanning two exons) through being synthetically created. Nor do they avoid the consequences of being short by making possible reactions that do not occur in our cells, such as PCR. While PCR has changed the practice of medicine and revolutionized biotechnology, Ambry shows that it does not save short DNAs. After its DNA primer claims were invalidated, Myriad settled with Ambry and many of its other competitors.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions